We calculated scores for angiotensin-converting enzyme 2 (ACE2), which is targeted by SARS-CoV-2 for infection of host cells (Walls et al., 2020), and the top drug candidate, ethoxzolamide, was selected for validation analysis (Figure 7B). Here, ACE2 is linked to infection.